TLDR
- ATHA jumps ~68% as Athira lands Phase 3 lasofoxifene rights and funding.
- Athira powers ATHA higher with a Phase 3 breast cancer deal and $90M raise.
- ATHA spikes near $8, then steadies as Athira adds Phase 3 assets and cash.
- Athira reshapes its pipeline as ATHA surges on lasofoxifene and financing news.
- ATHA rockets after Athira secures Phase 3 ELAINE-3 program and $90M cash.
Athira Pharma (ATHA) soared nearly 68% to around $6.94 following a major acquisition and financing deal.
Athira Pharma, Inc., ATHA
The stock surged sharply in early trading, briefly nearing $8, before stabilizing between $6.80 and $7.00 as the session continued. This breakout came after Athira secured exclusive rights to develop lasofoxifene, a Phase 3 drug candidate for metastatic breast cancer.
Lasofoxifene Acquisition Triggers Market Momentum
Athira Pharma signed a licensing agreement with Sermonix Pharmaceuticals to develop and commercialize lasofoxifene in most global markets. The agreement excludes Asia and certain Middle Eastern countries but gives Athira broad control over the candidate’s development path. Lasofoxifene is currently in the Phase 3 ELAINE-3 trial, which has passed 50% enrollment.
The Phase 3 program targets ESR1-mutant metastatic breast cancer patients who previously received aromatase inhibitors and CDK4/6 inhibitors. Athira plans to position lasofoxifene as a new standard of care for this patient population. The drug’s profile suggests it could offer better tolerability and potential bone protection due to its selective estrogen receptor modulation.
Preliminary data from earlier ELAINE studies indicated promising outcomes, including prolonged progression-free survival in previously treated patients. The Phase 3 readout is expected by mid-2027, with commercialization milestones tied to the drug’s regulatory progress. With a global license in hand, Athira now holds the reins to a potentially pivotal therapeutic asset.
Private Placement Strengthens Capital Base Through 2028
Athira also closed a $90 million private placement to fund the lasofoxifene program and support other pipeline assets. The deal includes the sale of common stock and warrants, with potential future proceeds of up to $146 million if exercised. The financing was co-led by top healthcare-focused firms including Perceptive Advisors, TCGX, and Commodore Capital.
Under the terms, Athira will issue approximately 5.4 million shares of common stock and pre-funded warrants for 8.8 million shares. The accompanying Series A and B warrants could add significant capital if converted, with exercise prices set at $6.35 and $7.62, respectively. The private placement is expected to close around December 23, 2025, subject to standard conditions.
Athira will use the proceeds to fund lasofoxifene’s continued development and support ATH-1105, its ALS program, among other priorities. With this capital boost, the company expects its cash runway to extend into 2028. This supports a focused execution strategy around late-stage trials and regulatory submissions.
Strategic Shift Signals New Growth Phase for Athira
The lasofoxifene deal marks a clear shift in Athira’s development strategy toward oncology and late-stage programs. The company is leveraging this move to diversify beyond neurology, where it has previously focused. The addition of a near-term Phase 3 asset strengthens the company’s pipeline and aligns with its push for value creation.
Athira’s leadership emphasized clarity and urgency in advancing the lasofoxifene program, aiming for regulatory success and commercial impact. The structure of the deal includes milestone-based payouts and modest royalty obligations to Sermonix. This setup allows Athira to control costs while pursuing long-term revenue generation.
With ATHA stock up sharply and funding secured, Athira Pharma has repositioned itself as a player in the oncology therapeutics space. The company now holds rights to a potential best-in-class endocrine therapy and has the capital to advance its mission. As the ELAINE-3 trial progresses, all focus turns to data in 2027 and the path to approval.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
